St. John’s Wort

Selected References:

  • Alzahrani MA, et al. 2023 Effect of St. John’s wort (Hypericum perforatum L.) on Male Sexual and Reproductive Health: A Narrative Review. Biomedicines. 11(10):2800.  
  • Barrett B, et al. 1999. Assessing the risks and benefits of herbal medicine: An overview of scientific evidence. Altern Ther Health Med 5(4):40-49.  
  • Clauson KA, et al. 2008. Clinically relevant safety issues associated with St. John’s wort product labels. BMC Complement Altern Med; 8:42. 
  • Fetrow CW and Avila JR. 1999. Professional’s Handbook of Complementary and Alternative Medicines. Springhouse, PA: Springhouse Corporation.  
  • Grush LE, et al. 1998. St. John’s wort During Pregnancy. JAMA 280(18):1566. 
  • Kaygusuz M, et al. 2021. TCM use in pregnant women and nursing mothers: A study from Turkey. Complement Ther Clin Pract. 42:101300.  
  • Klier CM, et al. 2006. St. John’s wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants. J Clin Psychiatry. 67(2):305-309.  
  • Kolding L, et al. 2015. Hypericum perforatum use during pregnancy & pregnancy outcome. Reprod Toxicol; 58:234-7.  
  • LeeA, et al. 2003. The safety of St. John’s wort (Hypericum perforatum) during Breast-feeding. J Clin Psychiatry 64(8):966-968.  
  • McCloskey LR, et al. 2021. Contraception for Women with Psychiatric Disorders. Am J Psychiatry; 178(3):247-255.  
  • Moretti ME, et al. 2009 Evaluating the safety of St. John’s wort in human pregnancy. Reprod Toxicol. 28(1):96-99.  
  • Nordeng H and Havnen GC. 2004. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Safety 13:371-380.  
  • Ondrizek RR, et al. 1999. Inhibition of human sperm motility by specific herbs used in alternative medicine. J Assist Reprod Genet 16(2):87-91.  
  • Schafer W, et al. 2021. Characterization of pregnancies exposed to St. John’s wort and their outcomes: A claims data analysis. Reprod Toxicol 102:90-97. 
  • Spiess D, et al. 2022. Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy. Front Pharmacol. 13:882997.  
  • United Stated Food and Drug Administration (FDA). 2021. Dietary Supplements. Available at: https://www.fda.gov/consumers/consumer-updates/dietary-supplements.  
  • United Stated Food and Drug Administration (FDA). 2024. Dietary Supplements. Available at: https://www.fda.gov/food/dietary-supplements.  

 

 

St. John’s Wort

Selected References:

  • Anderka M, et al. 2012. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. Jan;94(1):22-30. 
  • Bartfai Z, et al. 2008. A population-based case-control teratologic study of promethazine use during pregnancy. Reprod Toxicol. 25:276-285. 
  • Corby DG, Shulman I. 1971. The effects of antenatal drug administration on aggregation of platelets of newborn infants. J Pediatr. 79:307-313. 
  • Czeizel AE, et al. 1999. The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol. 21(2):157-167. 
  • Gilboa SM, et al. 2009. National Birth Defects Prevention Study: Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol. 85(2):137-150. 
  • Hall PF. 1987. Use of promethazine (Phenergan) in labour (letter). Can Med Assoc J; 136:690-691. 
  • Heinonen OP, et al. 1997. Birth Defects and Drugs in Pregnancy, Littleton, Publishing Sciences Group, pp 323-324, 437. 
  • Hildebrandt HM. 1999. Maternal perception of lactogenesis time: a clinical report. J Hum Lact.15:317-323. 
  • Kullander S, Källén B. 1976. A prospective study of drugs and pregnancy. II. Anti-emetic drugs. Acta Obstet Gynecol Scand.55(2):105-111. 
  • Larrimer MB, et al. 2014. Antiemetic medications in pregnancy: a prospective investigation of obstetric and neurobehavioral outcomes. Am J Obstet Gynecol 270: e1-e7. 
  • Messinis IE, et al. 1985. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest.8:143-146. 
  • Ngo E, et al. 2022. Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. Basic Clin Pharmacol Toxicol. 130(1): 171-181. 
  • Petik D, et al. 2008. A study of the potential teratogenic effect of large doses of promethazine used for a suicide attempt by 32 pregnant women. Toxicol Ind Health; 24(1-2):87-96. 
  • Petik D, et al. 2012. A study of the risk of mental retardation among children of pregnant women who have attempted suicide by means of a drug overdose. J Inj Violence Res. Jan;4(1):10-19. 
  • Schrager NL, et al. 2021. Trends in first-trimester nausea and vomiting of pregnancy and use of select treatments: Findings from the National Birth Defects Prevention Study. Paediatr Perinat Epidemiol. 2021 Jan;35(1):57-64.  
  • Starke PR, et al. 2005. Boxed warning added to promethazine labeling for pediatric use. NEJM 2005;352:2653. 
  • Whaun JM, et al. 1980. Effect of prenatal drug administration on maternal and neonatal platelet aggregation and PF4 release. Haemostasis; 9:226-237. 

St. John’s Wort

Selected References:

  • Abheiden CNH, et al. 2024. Systemic lupus erythematosus is associated with an increased frequency of spontaneous preterm births: systematic review and meta-analysis. Am J Obstet Gynecol, 231(4):408-416.e21. 
  • Acevedo M, et al. 2017. Breastfeeding initiation, duration, and reasons for weaning in patients with systemic lupus erythematosus. Rheumatol Int, 37(7):1183-1186. 
  • Akbari A, et al. 2025. Recurrent pregnancy loss and fetal complete heart block as the initial manifestations of maternal systemic lupus erythematosus: a case report on the diagnostic and preventive role of anti-SSA (Ro) antibodies. BMC Pregnancy Childbirth, 25(1):731. 
  • Alamdarloo SM, et al. 2025. Beyond the autoimmune spectrum, evaluating ovarian health in systemic lupus erythematosus patients: a case-control study. Health Sci Rep, 8(12):e71597. 
  • Alonaizan A, et al. 2024. Hyperlipidemia in Saudi Arabian patients with systemic lupus erythematosus. Cureus, 16(11):e74653.  
  • Al Rayes H, et al. 2024. Adverse impact of systemic lupus erythematosus on pregnancy outcomes: a Saudi Arabia retrospective multi-center study. Open Access Rheumatol, 16:31-41. 
  • Alrifai N, et al. 2025. Maternal and fetal outcomes in those with autoimmune connective tissue disease. Clin Rheumatol, 44(1):391-401.  
  • American Institute of Ultrasound in Medicine. 2020. AIUM practice parameter for the performance of fetal echocardiography. J Ultrasound Med, 39(1): E5-16. 
  • Andreatidis B, et al. 2025. Thrombotic thrombocytopenic purpura in pregnancy: a case report and literature review. Obstet Med, 1753495X251338163.  
  • Arkema EV, et al. 2016. What to expect when expecting with systemic lupus erythematosus (SLE): a population-based study of maternal and fetal outcomes in SLE and pre-SLE. Arthritis Care Res, 68:988–994. 
  • Authreya A J, et al. 2022. Fetal flat-facies on prenatal ultrasound: is it chondrodysplasia punctata? A retrospective chart review of 62 fetuses. Journal of Fetal Medicine, 9(02):35-43. 
  • Bedoya-Loaiza JE, et al. 2025. Maternal and fetal outcomes in pregnant patients with systemic lupus erythematosus: a study from a Latin American developing country. Lupus, 34(8):864-873. 
  • Blask AR. 2018. Severe nasomaxillary hypoplasia (Binder phenotype) on prenatal US/MRI: an important marker for the prenatal diagnosis of chondrodysplasia punctata. Pediatric radiology, 48(7):979-991. 
  • Buyon JP, et al. 2015. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med, 163:153–163. 
  • Cadir EK, et al. 2024. The effect of lupus on pregnancy and the foetus: should we really be worried? A single-centre retrospective study. Mediterr J Rheumatol, 35(3):464-468.  
  • Carvalheiras G, et al. 2010. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin Rev Allergy Immunol, 38(2-3):302-306. 
  • Cha JH, et al. 2023. The risk of pediatric cardiovascular diseases in offspring born to mothers with systemic lupus erythematosus: a nationwide study. Front Pediatr, 11:1294823.  
  • Clowse ME, et al. 2008. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol, 199:127 e1–6. 
  • Collison J. 2018. Systemic lupus erythematosus: effects of disease activity on pregnancy outcomes. Nat Rev Rheumatol, 14(1):4. 
  • Cortés-Hernández J, et al. 2002. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology, 41(6):643-650.  
  • Davidov D, et al. 2021. Maternal systemic lupus erythematosus (SLE) high risk for preterm delivery and not for long-term neurological morbidity of the offspring. Journal of Clinical Medicine, 10(13):2952. de Rezende RPV, et al. 2025. Tripled and sustained change in pregnancy-related annual mortality rates with systemic lupus erythematosus involvement: a nationwide temporal trends study, Brazil, 2006-2022. Adv Rheumatol, 65(1):12. 
  • Dhital R, et al. Adverse pregnancy outcomes across SLE subgroups: significance of cardiovascular events. Lupus Sci Med, 12(1):e001507. 
  • Diaz T, et al. 2025. Long-term outcomes of children born to anti-Ro antibody-positive mothers with and without rheumatic disease. Arthritis Care Res (Hoboken), 77(7):848-854. 
  • Do SC, et al. 2020. Does hydroxychloroquine protect against preeclampsia and preterm delivery in systemic lupus erythematosus pregnancies? Am J Perinatol,37(9):873-880. 
  • Dong Y, et al. 2019. Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. Clin Rheumatol, 39(2):319-325. 
  • Du Y, et al. 2024. Primary ovarian insufficiency consequence of autoimmune diseases: a bidirectional two-sample Mendelian randomization study. Front Endocrinol (Lausanne), 15:1417896.  
  • Ekblom-Kullberg S, et al. 2009. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol, 38(5):375-380.  
  • Elahi T, et al. 2024. Relationship of lupus nephritis and pregnancy: a narrative review. World J Nephrol, 13(4):99700. 
  • Elfving P, et al. 2024. Pregnancies in patients with systemic lupus erythematosus during 2000-2018 in Finland: a case-control study. Rheumatol Int, 44(6):1101-1109. 
  • Fang QY, et al. 2025. Pregnancy outcomes and risk factors for thrombocytopenia in pregnant patients with systemic lupus erythematosus. BMC Pregnancy Childbirth, 25(1):344.  
  • Fu PH, et al. 2024. Neonatal sex and maternal factors associated with small-for-gestational-age neonates: a nationwide population-based study. Health Sci Rep, 7(9):e70093.  
  • Fu W, et al. 2026. Clinical features of non-criteria obstetric antiphospholipid syndrome: a retrospective cohort study on antibody-based risk classification and pregnancy outcomes. BMC Pregnancy Childbirth, 26(1):139.  
  • Giannakaki AG, et al. 2025. Current approaches to the management of rheumatic diseases in pregnancy: risk stratification, therapeutic advances, and maternal-fetal outcomes. J Pers Med, 15(9):406.  
  • Gerede A, et al. 2025. Systemic lupus erythematosus in pregnancy. Med Sci (Basel), 13(3):174. 
  • Hammam N, et al. 2026. Machine learning-based identification of factors associated with spontaneous abortion in patients with Systemic lupus erythematosus (SLE): Insights from the Egyptian College of Rheumatology (ECR)-SLE cohort. Lupus, 9612033261415984.  
  • Handa R, et al. 2006. Systemic lupus erythematosus and pregnancy. J Assoc Physicians India, 54(1):19-21.  
  • Hartanto AI, et al. 2025. Postpartum uterine atony complicating labor in a patient with systemic lupus erythematosus: a case report. SAGE Open Med Case Rep, 13:2050313X251344026. 
  • He L, et al. 2025. Impact of disease activity on pregnancy outcomes and risk factors for fetal loss in systemic lupus erythematosus: a single-center cohort study. Ginekol Pol, 96(8):661-669. 
  • Hwang YM, et al. 2024. Maternal-fetal outcomes in patients with immune-mediated inflammatory diseases, with consideration of comorbidities: a retrospective cohort study in a large U.S. healthcare system. EClinicalMedicine, 68:102435.  
  • Isojima S, et al. 2024. Pregnancy outcomes in Australian patients with systemic lupus erythematosus. Intern Med J, 54(11):1876-1882.  
  • Khalayli N, et al. 2025. Lupus pneumonitis in neonatal lupus: a case report. J Med Case Rep, 19(1):489.  
  • Khamashta MA. 2006. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol, 20(4):685-694.  
  • Khanmirzaei A, et al. 2025. Diffuse alveolar haemorrhage as the initial presentation of systemic lupus erythematosus possibly triggered by Rhogam injection in a 24-year-old pregnant woman: a case report. Mod Rheumatol Case Rep, 9(2):rxaf001.  
  • Khogali HI, et al. 2023. Maternal and fetal health outcomes in systemic lupus erythematosus pregnancies in the Emirati population: a comparative study. Lupus, 32(12):1453-1461.  
  • Knudsen SS, et al. 2019. Maternal rheumatoid arthritis and systemic lupus erythematosus and risk of cryptorchidism and hypospadias in boys: a Danish nationwide study. Rheumatology (Oxford), 59(8):1871-8177. 
  • Kothari R, et al. 2016. Reproductive health in systemic lupus erythematosus, an experience from government hospital in Western India. J Assoc Physicians India, 64(12):16-20.  
  • Kumar A, et al. 2025. Postpartum renal cortical necrosis:  experience from a tertiary care center in India. J Nephrol, 38(6):1609-1618. 
  • Lang T, et al. 2024. Investigation of the causal relationship between autoimmune diseases and premature ovarian insufficiency. Reprod Sci, 32(1):176-186.  
  • Limquiaco KNY, Salido EO. 2024. Complete congenital heart block in the offspring of an asymptomatic woman with isolated high titer anti-Ro antibody. Acta Med Philipp, 58(1):84-89.  
  • Liu H, et al. 2025. Risk factors for adverse maternal and fetal outcomes in SLE patients: a systematic review and meta-analysis. Front Med (Lausanne), 12:1573573.  
  • Liu L, et al. 2025. Risk stratification and subgroup analysis of systemic lupus erythematosus patients with pregnancy: based on a 13-year multicenter cohort study. Clin Rheumatol, 44(10):3909-3921. 
  • Lucas AM, et al. 2025. Second trimester kidney function and adverse pregnancy outcomes among patients with lupus. Kidney360, 6(6):983-996. 
  • Ma J, et al. 2024. High-risk groups of neonatal lupus erythematosus in term infants: a birth cohort study. Eur J Pediatr, 183(1):149-155. 
  • Ma J, et al. 2025. Long-term follow-up of offspring of mothers with systemic lupus erythematosus: an observational study. Clin Rheumatol, doi: 10.1007/s10067-025-07893-z. Epub ahead of print. 
  • Madazli R, et al. 2010. Systemic lupus erythematosus and pregnancy. J Obstet Gynaecol, 30(1):17-20.  
  • Marder W. 2014. Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. Lupus Sci Med, 1(1):e000034. 
  • Martín-Portugués M, et al. 2025. Elevated pre-eclampsia risk in lupus nephritis and antiphospholipid syndrome: a nationwide Spanish registry analysis. Rheumatology (Oxford), keaf484.  
  • Martinez-Rueda JO, et al. 1996. Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus, 5(1):113-119.  
  • Mathesan M, Ethirajan S. 2024. Triumph over adversity: a comprehensive case series on successful pregnancy outcomes in antiphospholipid antibody (APLA)-positive patients. Cureus, 16(4):e59088.  
  • Misztal MC, et al. 2025. Genetics of neonatal lupus erythematosus risk and specific manifestations. J Rheumatol, 52(1):52-57.  
  • Mohan P, et al. 2025. Pregnancy outcomes in women with systemic lupus erythematosus (SLE): a matched-observational study from India. Int J Rheum Dis, 28(6):e70328.  
  • Mok CC, et al. 2001. Pregnancy in systemic lupus erythematosus. Postgrad Med J, 77(1):157-165.  
  • Moyer A, Edens C. 2024. Impact of systemic lupus erythematosus on conception: insights into infertility, fertility preservation, assisted reproductive technology, and pregnancy outcomes. Semin Reprod Med, 42(3):209-227.  
  • Murari K, et al. 2025. Congenital complete heart block requiring temporary pacemaker placement at birth: a case report. Semin Cardiothorac Vasc Anesth, 29(3):219-224. 
  • Murvai VR, et al. 2025 Antiphospholipid syndrome in pregnancy: a comprehensive literature review. BMC Pregnancy Childbirth, 25(1):337.  
  • Nalli C, et al. 2017. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus, 26(5):552-558. 
  • Ndarugendamwo AM, et al. 2025. Massively elevated sFlt1/PlGF in a pregnant patient with fetal growth restriction and perinatal death in the context of a systemic lupus erythematosus. BMJ Case Rep, 18(2):e258131. 
  • Nossent JC, et al. 2024. Comparison of pregnancy outcomes between indigenous and non-indigenous lupus patients. Intern Med J, 54(9):1465-1470.  
  • Nusbaum J, et al. 2020. Breast feeding in the systemic lupus erythematosus patient. Lupus, 29(10):1314-1315.. 
  • Nusbaum JS, et al. 2020. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc, 95(2):384-394.  
  • Petri M, et al. 1991. Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy experience. Arthritis Rheum, 34(1):1538.  
  • Petri M. 2000. Systemic lupus erythematosus: women’s health issues. Bull Rheum Dis, 49(1):1-3.  
  • Petri M. 2020. Pregnancy and systemic lupus erythematosus. Best Pract Res Clin Obstet Gynaecol, 64:24-30.  
  • Phansenee S, et al. 2018. Pregnancy outcomes among women with systemic lupus erythematosus: a retrospective cohort study from Thailand. Lupus, 27(1):158-164.  
  • Polić A, Običan SG. 2020. Pregnancy in systemic lupus erythematosus. Birth Defects Res, 112(15):1115-1125.  
  • Repicky J, et a. 2025. Spontaneous conversion of fetal heart block to sinus rhythm post externalized pacemaker placement in an undiagnosed mother with lupus antibodies. J Matern Fetal Neonatal Med, 38(1):2428390.  
  • Rezaieyazdi Z, et al. 2024. Clinical and serological findings of patients with antiphospholipid syndrome in Mashhad, Iran, from 2008 to 2018: a retrospective, descriptive, cross-sectional study. Eur J Rheumatol, 11(4):390-398. 
  • Saavedra MÁ, et al. 2024. Active but not quiescent lupus nephritis during pregnancy is associated with a higher rate of adverse obstetric outcomes: analysis of a prospective cohort. Int J Gynaecol Obstet, 167(1):420-426.  
  • Sapantzoglou I, et al. 2023. Congenital heart block and its association with anti-Ro and anti-La antibodies in pregnancy: a case report of a rare entity and a review of the current evidence. Cureus, 15(9):e45832. 
  • Shao S, et al. 2025. The long-term development outcomes of the offspring born to patients with systemic lupus erythematosus: a cross-sectional study. Eur Child Adolesc Psychiatry, 34(8):2359-2368. 
  • Sieiro Santos C, et al. 2025. Pregnancy outcomes in connective tissue diseases: a 30-year study of 465 cases from a single-center Spanish registry with insights on hydroxychloroquine use. ARP Rheumatol, 4(1):29-36. 
  • Silver R, et al. 2023. Society for Maternal-Fetal Medicine Consult Series# 64: Systemic lupus erythematosus in pregnancy. J of Obstet Gynecol, 228(3):B41-B60. 
  • Silverman E & Jaeggi E. 2010. Non-cardiac manifestations of neonatal lupus erythematosus. Scand J Immunol, 72(3):223-225.  
  • Singh AG & Chowdhary VR. 2014. Pregnancy-related issues in women with systemic lupus erythematosus. Int J Rheum Dis, 18(2):172-181. 
  • Skorpen CG, et al. 2018. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis, 77(2):264-269.  
  • Smyth A, et al. 2010. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol, 5:2060–2068. 
  • Soares PM, et al. 2007. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum, 56(7):2352-2361.  
  • Suehiro RM, et al. 2008. Testicular Sertoli cell function in male systemic lupus erythematosus. Rheumatology (Oxford), 47:1692–1697. 
  • Sammaritano LR, et al. (2020). 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis care & research, 72(4):461-488. 
  • Shahwar DE, et al. 2024. A comparison of obstetric outcomes in antiphospholipid syndrome among pregnant women with systemic lupus erythematosus. Cureus, 16(6):e62126. 
  • Sun C, et al. 2025. Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review. Arch Gynecol Obstet, 312(4):1025-1036.  
  • Sun W, et al. 2025. Neonatal lupus erythematosus: an acquired autoimmune disease to be taken seriously. Ann Med, 57(1):2476049. 
  • Sun W, et al. 2025. IgG-associated hypocomplementemia in neonatal lupus: a retrospective multicenter study. J Inflamm Res, 11;18:3419-3429. 
  • Sun W, et al. 2025. Neonatal lupus erythematosus presenting with congenital heart block: clinical characteristics and follow-up. Clin Rheumatol, 44(4):1581-1587.  
  • Tan EM, et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 25(1):1271.  
  • Tan Z, et al. 2024. Causal pathways in preeclampsia: a Mendelian randomization study in European populations. Front Endocrinol (Lausanne), 15:1453277.  
  • Tang P, et al. 2025. Case Report: Siblings with neonatal lupus erythematosus. Front Pediatr, 13:1518881.  
  • Teng YKO, et al. 2018. An evidence-based approach to pre-pregnancy counseling for patients with systemic lupus erythematosus. Rheumatology (Oxford), 57(10):1707-1720.  
  • Thanh CM, et al. 2025. A multi-institutional case series of neonatal lupus erythematosus without cardiac involvement from Vietnam. Case Rep Pediatr, 2025:5727878. 
  • Tiseo, BC, et al. 2019. Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients. Lupus, 28(1):59-65. 
  • Turgay B, et al. 2025. Inflamed pathways to motherhood: evaluating obstetric and neonatal outcomes in rheumatic pregnancies. J Clin Med, 14(16):5692. 
  • Vinet E. 2014. Neurodevelopmental disorders in children born to mothers with systemic lupus erythematosus. Lupus, 23(11):1099–1104. 
  • Wang QH, et al. 2026. Current risk factors for male infertility and semen parameters: an umbrella review of systematic reviews and meta-analyses. Asian J Androl, doi: 10.4103/aja202552. Epub ahead of print. 
  • Wichert-Schmitt B, et al. 2025. Pericardial tamponade in pregnancy due to undiagnosed systemic lupus erythematosus: a case report. Eur Heart J Case Rep, 9(9):ytaf388. 
  • Xu Y, et al. 2025. Pregnancy characteristics of patients with systemic lupus erythematosus with different onset times and their risk of adverse pregnancy outcomes: a retrospective cohort study. Lupus Sci Med, 12(1):e001529.  
  • Xu Y, et al. 2025. Predictors of adverse pregnancy outcomes in systemic lupus erythematosus: a retrospective cohort study. Clin Rheumatol, doi: 10.1007/s10067-025-07882-2. Epub ahead of print.  
  • Yang MJ, et al. 2015. Pregnancy outcome of systemic lupus erythematosus in relation to lupus activity before and during pregnancy. J Chin Med Assoc, 78(4):235-240. 
  • Yang X. 2022. Clinical features, autoantibodies, and outcome of neonatal lupus erythematosus. Fetal and Pediatric Pathology, 41(3):436-442. 
  • Zhang X, et al. 2024. Autoimmune diseases and risk of gestational diabetes mellitus: a Mendelian randomization study. Acta Diabetol, 61(2):161-168.  
  • Zheng L, et al. 2025. The impact of early pregnancy disease control in systemic lupus erythematosus patients receiving comprehensive pharmaceutical care on pregnancy outcomes and offspring long-term health. BMC Pregnancy Childbirth, 25(1):1035. 
  • Zhu S, et al. 2024. Systemic lupus erythematosus and pregnancy complications and outcomes: a Mendelian randomization study and retrospective validation. Int J Womens Health, 16:891-902.  
  • Zhu T, et al. 2024. Causal relationship between systemic lupus erythematosus and adverse pregnancy outcomes: a two-sample Mendelian randomized study. Heliyon, 10(15):e35401. 
  • Zou X, et al. 2025. Bibliometric analysis of systemic lupus erythematosus during pregnancy from 2003 to 2024. Immunol Med, 48(4):318-334. 

 

St. John’s Wort

Selected References:

  • Almgren M, et al. 2009. Population-based study of antiepileptic drug exposure in utero—influence on head circumference in newborns. Seizure 18(10):672-675. 
  • Artama M, et al. 2013. Drug and Pregnancy Group: Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf 36(5):359-369.  
  • Bech BH, et al. 2014. Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population-based cohort study. BMJ 349:g5159. 
  • Berry-Noronha A, et al. 2025. Risk of Adverse Pregnancy Outcomes Associated With Antiseizure Medications and Their Indications: A Systematic Review and Meta-Analysis. Neurology; 104(3):e210233 
  • Bjork M-H, et al 2022. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol. Jul 1;79(7): 727. 
  • Brandlistuen RE, et al. 2017. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS ONE 12(7): e0181042. 
  • Cohn DF, et al. 1982. The effect of anticonvulsant drugs on the development of male rats and their fertility. J Neurol Neurosurg Psychiatry; 45(9):844-6.   
  • Christensen et al. 2013.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309(16):1696-703.  
  • Christensen J, et al. 2024. Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries. Lancet Reg Health Eur; 38:100849 
  • Clonazepam. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017533s055lbl.pdf. Revised 2016. Accessed February 2026. 
  • Daugaard C, et al. 2020. Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones. JAMA Netw Open 3(11):e2025570. 
  • Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals 6(10):1221-1286. 
  • Kilic D, et al. 2014. Birth outcomes after prenatal exposure to antiepileptic drugs–a population-based study. Epilepsia 55(11):1714-1721.  
  • Lin, A, et al. 2004. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol 70(8):534-536. 
  • Oberlander TF, et al. 2004. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65(2):230-237.  
  • Soussan C. et al. 2014 Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 70:1361-6. 
  • Vajda FJE, et al. 2014. The teratogenicity of the newer antiepileptic drugs – an update. Acta Neurol Scand 130(4):234-238. 
  • Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261(3):579-588.  
  • Veiby G, et al. 2015. Epilepsy and recommendations for breastfeeding. Seizure 28:57-65. 
  • Veroniki, AA, et al. 2017. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open 7(7):e017248. 
  • Weinstock L, et al. 2001. Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. Psychother Psychosom 70(3):158-162. 

St. John’s Wort

Selected References:

  • Bodamer OA, et al. 2010. Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr.; 160(23-24):600-4. 
  • Cox TM, et al. 2008. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphonate therapy, use of biomarkers, and bone disease monitoring. J Inherit Metab Dis. 31:319-336. 
  • Dornelles AD, et al. 2014. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? Clin Ther; 36(6):990-1.  
  • Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol; 190:435–41. 
  • Giannubilo SR, et al. 2015. Replacement Therapy for Gaucher Disease during Pregnancy: A Case Report. J Reprod Infertil;16(1):53-7.  
  • Giraldo P, et al. 2021. Novel Management and Screening Approaches for Haematological Complications of Gaucher’s Disease. J Blood Med; 12:1045-1056.  
  • Granovsky-Grisaru S, et al. 2011. The management of pregnancy in Gaucher disease. Eur I Obstet Gynecol Reprod Biol. 156: (1) 3-8. 
  • Hughes DA, Pastores GM. 2000 [Updated December 7, 2023]. GeneReviews: Gaucher Disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1269/. Accessed 12/2023. 
  • Komninaka, V, et al. 2020. Outcomes of pregnancies in patients with Gaucher Disease: The experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece. Eur J Obstet Gynecol Reprod Biol; 254: 181-187. doi:10.1016/j.ejogrb.2020.09.027 
  • Lau H, et al. 2018. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells Mol Dis; 68:226-231. 
  • Lukina E, et al. 2020. Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials. JIMD Rep; 57(1):76-84.  
  • Mamopoulos A M, et al. 2009. Gaucher disease and pregnancy. J Obstet Gynaecol; 29: 240-242.
  • Rosenbaum H. 2015. Management of women with Gaucher disease in the reproductive age. Thromb Res; 136(2):489.  
  • Revel-Vilk S, et al. 2026. Maternal and Fetal Outcomes in Imiglucerase-Treated Patients with Gaucher Disease: Real-World Evidence From the International Collaborative Gaucher Group (ICGG) Gaucher Registry Pregnancy Sub-Registry. J Inherit Metab Dis; 49(2):e70161.  
  • Sakarelou N, et al. 1999. Pregnancy in Gaucher disease, Eur J Obstet Gynecol Reprod Biol; 83(1):113-4.  
  • Sekijima Y, et al. 2010. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther; 32(12):2048-52. 
  • Simchen MJ, et al. 2011. Impaired platelet function and peripartum bleeding in women with Gaucher disease. Thromb Haemost;105(3):509-14.  
  • Sugiura T, et al. 2022. Gaucher disease carrier with gestational thrombocytopenia and anemia: a case report. J Med Case Rep. 13;16(1):203. 
  • Zimran A, et al. 2009. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events. Blood Cells Mol Dis. 43:264-288. 
  • Zimran, A. 2011. How I treat Gaucher Disease. Blood; 11
St. John’s Wort
February 1, 2026		 page {PAGENO} of {PAGETOTAL}